

Antonella Caivano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8379169/publications.pdf>

Version: 2024-02-01

43
papers

1,287
citations

304743

22
h-index

361022

35
g-index

43
all docs

43
docs citations

43
times ranked

2089
citing authors

#	ARTICLE	IF	CITATIONS
1	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. <i>Tumor Biology</i> , 2015, 36, 9739-9752.	1.8	159
2	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. <i>Oncotarget</i> , 2016, 7, 6676-6692.	1.8	86
3	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1935-1946.	7.0	75
4	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 97-103.	4.4	65
5	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 460.	4.1	62
6	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5796-5807.	7.0	56
7	HIF-1 α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 847-858.	7.0	54
8	Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T cell responses in the absence of adjuvants. <i>European Journal of Immunology</i> , 2011, 41, 2573-2584.	2.9	48
9	Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies. <i>Stem Cells International</i> , 2018, 2018, 1-11.	2.5	47
10	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1424-1432.	1.3	43
11	Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy. <i>Leukemia</i> , 2021, 35, 661-678.	7.2	40
12	Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1022.	4.1	36
13	Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells. <i>PLoS ONE</i> , 2012, 7, e31464.	2.5	32
14	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2017, 8, e2849-e2849.	6.3	32
15	Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. <i>Oncogene</i> , 2012, 31, 2258-2269.	5.9	31
16	Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1183.	4.1	31
17	Use of Fusion Proteins and Prokaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection. <i>Current HIV Research</i> , 2003, 1, 441-446.	0.5	31
18	Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex. <i>Vaccine</i> , 2003, 21, 1502-1509.	3.8	28

#	ARTICLE	IF	CITATIONS
19	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2016, 7, 491.	3.5	27
20	Do we need to distinguish exosomes from microvesicles in hematological malignancies?. <i>Leukemia</i> , 2017, 31, 2009-2010.	7.2	27
21	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 17514-17534.	4.1	23
22	Epha3 acts as proangiogenic factor in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 34298-34309.	1.8	23
23	HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from <i>Geobacillus stearothermophilus</i> induces sustained humoral and cellular immune responses in the absence of IFN γ production by CD4+ T cells. <i>Virology</i> , 2010, 407, 296-305.	2.4	22
24	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5674-5699.	4.1	22
25	An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 249-258.	3.1	20
26	Hit Recycling: Discovery of a Potent Carbonic Anhydrase Inhibitor by <i>in Silico</i> Target Fishing. <i>ACS Chemical Biology</i> , 2015, 10, 1964-1969.	3.4	19
27	A Pyrazolo[3,4- <i>d</i>]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. <i>Oncotarget</i> , 2016, 7, 65171-65184.	1.8	18
28	Comparative analysis of new innovative vaccine formulations based on the use of procaryotic display systems. <i>Vaccine</i> , 2007, 25, 1993-2000.	3.8	17
29	A multimeric immunogen for the induction of immune memory to beta β amyloid. <i>Immunology and Cell Biology</i> , 2011, 89, 604-609.	2.3	17
30	Future in the Past: <i>Azorella glabra</i> Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3348.	4.1	17
31	EphA3 targeting reduces <i>in vitro</i> adhesion and invasion and <i>in vivo</i> growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 483-496.	4.4	15
32	Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 3141-3160.	6.7	14
33	DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation. <i>Stem Cell Research and Therapy</i> , 2019, 10, 138.	5.5	12
34	Design of cassette vectors permitting cloning of all types of human TCR variable α and β regions. <i>Journal of Immunological Methods</i> , 2001, 255, 125-134.	1.4	8
35	A Pyrazolo[3,4- <i>d</i>]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2016, 7, 416.	3.5	8
36	Multiple Myeloma-Derived Extracellular Vesicles Impair Normal Hematopoiesis by Acting on Hematopoietic Stem and Progenitor Cells. <i>Frontiers in Medicine</i> , 2021, 8, 793040.	2.6	7

#	ARTICLE	IF	CITATIONS
37	Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis Through the Release of Extracellular Vesicles. <i>Frontiers in Oncology</i> , 2022, 12, 824562.	2.8	5
38	Advances in <i>Azorella glabra</i> Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization. <i>Molecules</i> , 2020, 25, 4890.	3.8	4
39	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 2458-2459.	1.3	3
40	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. <i>Tumor Biology</i> , 2016, 37, 217-225.	1.8	2
41	A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells. <i>Blood</i> , 2015, 126, 3254-3254.	1.4	1
42	EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody. <i>Blood</i> , 2013, 122, 3211-3211.	1.4	0
43	High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders. <i>Blood</i> , 2014, 124, 2917-2917.	1.4	0